SOST/Sclerostin: An Osteocyte-Derived Inhibitor of Bone Formation that Antagonizes Canonical Wnt Signaling

Principles of Bone Biology: Volume 1-2, Third Edition

Volumn , Issue , 2008, Pages 139-152

  van Bezooijen, Rutger L ^a   Papapoulos, Socrates E ^a   Hamdy, Neveen A T ^a   Löwik, Clemens W G M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67651141761     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00014-8     Document Type: Chapter

References (79)

1. M. Ai, S.L. Holmen, W. Van Hul, B.O. Williams and M.L. Warman (2005) Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol. Cell Biol 25 4946-4955.
2. O. Avsian-Kretchmer and A.J. Hsueh (2004) Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol. Endocrinol 18 1-12.
3. W. Balemans, E. Cleiren, U. Siebers, J. Horst and W. Van Hul (2005) A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 36 943-947.
4. W. Balemans, J.P. Devogelaer, E. Cleiren, E. Piters, E. Caussin and W. Van Hul (2007) Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J. Bone Miner. Res 22 708-716.
5. W. Balemans, M. Ebeling, N. Patel, E. Van Hul, P. Olson, M. Dioszegi, C. Lacza, W. Wuyts, E.J. Van Den, P. Willems, A.F. Paes-Alves, S. Hill, M. Bueno, F.J. Ramos, P. Tacconi, F.G. Dikkers, C. Stratakis, K. Lindpaintner, B. Vickery, D. Foernzler and W. Van Hul (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet 10 537-543.
6. W. Balemans, N. Patel, M. Ebeling, E. Van Hul, W. Wuyts, C. Lacza, M. Dioszegi, F.G. Dikkers, P. Hildering, P.J. Willems, J.B. Verheij, K. Lindpaintner, B. Vickery, D. Foernzler and W. Van Hul (2002) Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet 39 91-97.
7. W. Balemans and W. Van Hul (2007) The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology 148 2622-2629.
8. R. Baron, G. Rawadi and S. Roman-Roman (2006) Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol 76 103-127.
9. P. Beighton (1988) Sclerosteosis. J. Med. Genet 25 200-203.
10. P. Beighton, A. Barnard, H. Hamersma and W.A. van der (1984) The syndromic status of sclerosteosis and van Buchem disease. Clin. Genet 25 175-181.
11. Beighton, P., Hamersma, H., Brunkow, M. E. (2004). SOST-related sclerosting bone dysplasias. In “GeneReviews Genetics Disease Online Reviews at Gene-Test-Gene-Clinics” [database online] Available at http://www.geneclinics.org.
12. E. Bell, I. Munoz-Sanjuan, C.R. Altmann, A. Vonica and A.H. Brivanlou (2003) Cell fate specification and competence by Coco, a maternal BMP, TGFbeta and Wnt inhibitor. Development 130 1381-1389.
13. T. Bellido, A.A. Ali, I. Gubrij, L.I. Plotkin, Q. Fu, C.A. O’Brien, S.C. Manolagas and R.L. Jilka (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146 4577-4583.
14. C.N. Bennett, K.A. Longo, W.S. Wright, L.J. Suva, T.F. Lane, K.D. Hankenson and O.A. MacDougald (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc. Natl. Acad. Sci. USA 102 3324-3329.
15. B.M. Bhat, K.M. Allen, W. Liu, J. Graham, A. Morales, A. Anisowicz, H.S. Lam, C. McCauley, V. Coleburn, M. Cain, E. Fortier, R.A. Bhat, F.J. Bex and P.J. Yaworsky (2007) Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling. Gene 391 103-112.
16. L.M. Boyden, J. Mao, J. Belsky, L. Mitzner, A. Farhi, M.A. Mitnick, D. Wu, K. Insogna and R.P. Lifton (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med 346 1513-1521.
17. M.E. Brunkow, J.C. Gardner, J. Van Ness, B.W. Paeper, B.R. Kovacevich, S. Proll, J.E. Skonier, L. Zhao, P.J. Sabo, Y. Fu, R.S. Alisch, L. Gillett, T. Colbert, P. Tacconi, D. Galas, H. Hamersma, P. Beighton and J. Mulligan (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet 68 577-589.
18. E. Canalis, A.N. Economides and E. Gazzerro (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev 24 218-235.
19. H. Clevers (2006) Wnt/beta-catenin signaling in development and disease. Cell 127 469-480.
20. P. Ducy, C. Desbois, B. Boyce, G. Pinero, B. Story, C. Dunstan, E. Smith, J. Bonadio, S. Goldstein, C. Gundberg, A. Bradley and G. Karsenty (1996) Increased bone formation in osteocalcin-deficient mice. Nature 382 448-452.
21. D.L. Ellies, B. Viviano, J. McCarthy, J.P. Rey, N. Itasaki, S. Saunders and R. Krumlauf (2006) Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5(G171V) to modulate Wnt activity. J. Bone Miner. Res 21 1738-1749.
22. J.C. Gardner, R.L. van Bezooijen, B. Mervis, N.A. Hamdy, C.W. Lowik, H. Hamersma, P. Beighton and S.E. Papapoulos (2005) Bone mineral density in sclerosteosis: Affected individuals and gene carriers. J. Clin. Endocrinol. Metab 90 6392-6395.
23. D.A. Glass and G. Karsenty (2007) In vivo analysis of Wnt signaling in bone. Endocrinology 148 2630-2634.
24. Y. Gong, R.B. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A.M. Reginato, H. Wang, T. Cundy, F.H. Glorieux, D. Lev, M. Zacharin, K. Oexle, J. Marcelino, W. Suwairi, S. Heeger, G. Sabatakos, S. Apte, W.N. Adkins, J. Allgrove, M. Arslan-Kirchner, J.A. Batch, P. Beighton, G.C. Black, R.G. Boles, L.M. Boon, C. Borrone, H.G. Brunner, G.F. Carle, B. Dallapiccola, A. De Paepe, B. Floege, M.L. Halfhide, B. Hall, R.C. Hennekam, T. Hirose, A. Jans, H. Juppner, C.A. Kim, K. Keppler-Noreuil, A. Kohlschuetter, D. LaCombe, M. Lambert, E. Lemyre, T. Letteboer, L. Peltonen, R.S. Ramesar, M. Romanengo, H. Somer, E. Steichen-Gersdorf, B. Steinmann, B. Sullivan, A. Superti-Furga, W. Swoboda, M.J. van den Boogaard, W. Van Hul, M. Vikkula, M. Votruba, B. Zabel, T. Garcia, R. Baron, B.R. Olsen and M.L. Warman (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 513-523.
25. H. Hamersma, J. Gardner and P. Beighton (2003) The natural history of sclerosteosis. Clin. Genet 63 192-197.
26. Y. Han, S.C. Cowin, M.B. Schaffler and S. Weinbaum (2004) Mechanotransduction and strain amplification in osteocyte cell processes. Proc. Natl. Acad. Sci. USA 101 16689-16694.
27. J.R. Hens, K.M. Wilson, P. Dann, X. Chen, M.C. Horowitz and J.J. Wysolmerski (2005) TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J. Bone Miner. Res 20 1103-1113.
28. S.C. Hill, S.A. Stein, A. Dwyer, J. Altman, R. Dorwart and J. Doppman (1986) Cranial CT findings in sclerosteosis. AJNR Am. J. Neuroradiol 7 505-511.
29. S.L. Holmen, T.A. Giambernardi, C.R. Zylstra, B.D. Buckner-Berghuis, J.H. Resau, J.F. Hess, V. Glatt, M.L. Bouxsein, M. Ai, M.L. Warman and B.O. Williams (2004) Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J. Bone Miner. Res 19 2033-2040.
30. N. Itasaki, C.M. Jones, S. Mercurio, A. Rowe, P.M. Domingos, J.C. Smith and R. Krumlauf (2003) Wise, a context-dependent activator and inhibitor of Wnt signalling. Development 130 4295-4305.
31. M.L. Johnson, G. Gong, W. Kimberling, S.M. Recker, D.B. Kimmel and R.B. Recker (1997) Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am. J. Hum. Genet 60 1326-1332.
32. Y. Kato, A. Boskey, L. Spevak, M. Dallas, M. Hori and L.F. Bonewald (2001) Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J. Bone Miner. Res 16 1622-1633.
33. H. Keller and M. Kneissel (2005) SOST is a target gene for PTH in bone. Bone 37 148-158.
34. D.P. Kiel, S.L. Ferrari, L.A. Cupples, D. Karasik, D. Manen, A. Imamovic, A.G. Herbert and J. Dupuis (2007) Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men. Bone 40 587-596.
35. M.L. Knothe Tate, J.R. Adamson, A.E. Tami and T.W. Bauer (2004) The osteocyte. Int. J. Biochem. Cell Biol 36 1-8.
36. N. Kusu, J. Laurikkala, M. Imanishi, H. Usui, M. Konishi, A. Miyake, I. Thesleff and N. Itoh (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J. Biol. Chem. 278 24113-24117.
37. G.M. Lenk, G. Tromp, S. Weinsheimer, Z. Gatalica, R. Berguer and H. Kuivaniemi (2007) Whole genome expression profiling reveals a significant role for immune function in human abdominal aortic aneurysms. BMC Genomics 8 237.
38. O. Leupin, I. Kramer, N.M. Collette, G.G. Loots, F. Natt, M. Kneissel and H. Keller (2007) Control of the SOST bone enhancer by PTH via MEF2 transcription factors. J. Bone Miner. Res
39. R. Levasseur, D. LaCombe and M.C. De Vernejoul (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72 207-214.
40. X. Li, Y. Zhang, H. Kang, W. Liu, P. Liu, J. Zhang, S.E. Harris and D. Wu (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280 19883-19887.
41. R.D. Little, J.P. Carulli, R.G. Del Mastro, J. Dupuis, M. Osborne, C. Folz, S.P. Manning, P.M. Swain, S.C. Zhao, B. Eustace, M.M. Lappe, L. Spitzer, S. Zweier, K. Braunschweiger, Y. Benchekroun, X. Hu, R. Adair, L. Chee, M.G. FitzGerald, C. Tulig, A. Caruso, N. Tzellas, A. Bawa, B. Franklin, S. McGuire, X. Nogues, G. Gong, K.M. Allen, A. Anisowicz, A.J. Morales, P.T. Lomedico, S.M. Recker, P. Van Eerdewegh, R.R. Recker and M.L. Johnson (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70 11-19.
42. G.G. Loots, M. Kneissel, H. Keller, M. Baptist, J. Chang, N.M. Collette, D. Ovcharenko, I. Plajzer-Frick and E.M. Rubin (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 15 928-935.
43. B. Mao, W. Wu, G. Davidson, J. Marhold, M. Li, B.M. Mechler, H. Delius, D. Hoppe, P. Stannek, C. Walter, A. Glinka and C. Niehrs (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417 664-667.
44. B. Mao, W. Wu, Y. Li, D. Hoppe, P. Stannek, A. Glinka and C. Niehrs (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411 321-325.
45. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang and B.H. Mitlak (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 1434-1441.
46. Y. Ohyama, A. Nifuji, Y. Maeda, T. Amagasa and M. Noda (2004) Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology 145 4685-4692.
47. M. Ominsky, B. Stouch, G. Doellgast, J. Gong, J. Cao, Y. Gao, B. Tipton, R. Haldankar, A. Winters, Q. Chen, K. Graham, L. Zhou, M. Hale, A. Henry, D. Lightwood, A. Moore, A. Popplewell, M. Robinson, F. Vlasseros, J. Jolette, S.Y. Smith, P.J. Kostenuik, W.S. Simonet, D.L. Lacey and C. Paszty (2006) Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength. Proc. Am. Soc. Bone Miner. Res. Abstr
48. M. Ominsky, B. Stouch, G. Doellgast, J. Gong, J. Cao, Y. Gao, B. Tipton, R. Haldankar, A. Winters, Q. Chen, K. Graham, L. Zhou, M. Hale, A. Henry, D. Lightwood, A. Moore, A. Popplewell, M. Robinson, F. Vlasseros, J. Jolette, S.Y. Smith, P.J. Kostenuik, W.S. Simonet, D.L. Lacey and C. Paszty (2006) Sclerostin monoclonal antibody treatment increases bone strength in aged osteopenic ovariectomized rats. Proc. Am. Soc. Bone Miner. Res. 1161. Abstr
49. D. Padhi, B. Stouch, G. Jang, L. Fang, M. Darling, H. Glise, M. Robinson, S. Harris and E. Posvar (2007) Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. Proc. Am. Soc. Bone Miner. Res. 1129.
50. S. Piccolo, E. Agius, L. Leyns, S. Bhattacharyya, H. Grunz, T. Bouwmeester and E.M. De Robertis (1999) The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature 397 707-710.
51. S.M. Pockwinse, L.G. Wilming, D.M. Conlon, G.S. Stein and J.B. Lian (1992) Expression of cell growth and bone specific genes at single cell resolution during development of bone tissue-like organization in primary osteoblast cultures. J. Cell Biochem. 49 310-323.
52. K.E. Poole, R.L. van Bezooijen, N. Loveridge, H. Hamersma, S.E. Papapoulos, C.W. Lowik and J. Reeve (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19 1842-1844.
53. A.G. Robling, T. Bellido and C.H. Turner (2006) Mechanical loading reduces osteocyte expression of sclerostin protein. Proc. Am. Soc. Bone. Miner. Res Abstr
54. M. Semenov, K. Tamai and X. He (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280 26770-26775.
55. M.V. Semenov and X. He (2006) LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem. 281 38276-38284.
56. B. Sevetson, S. Taylor and Y. Pan (2004) Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J. Biol. Chem. 279 13849-13858.
57. D. Shoback (2007) Update in osteoporosis and metabolic bone disorders. J. Clin. Endocrinol. Metab. 92 747-753.
58. G. Silvestrini, P. Ballanti, M. Leopizzi, M. Sebastiani, S. Berni, M. Di Vito and E. Bonucci (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J. Mol.Histol
59. K. Staehling-Hampton, S. Proll, B.W. Paeper, L. Zhao, P. Charmley, A. Brown, J.C. Gardner, D. Galas, R.C. Schatzman, P. Beighton, S. Papapoulos, H. Hamersma and M.E. Brunkow (2002) A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 110 144-152.
60. S.A. Stein, C. Witkop, S. Hill, M.D. Fallon, L. Viernstein, G. Gucer, P. McKeever, D. Long, J. Altman, N.R. Miller, S.L. Teitelbaum and S. Schlesinger (1983) Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology 33 267-277.
61. M.K. Sutherland, J.C. Geoghegan, C. Yu, E. Turcott, J.E. Skonier, D.G. Winkler and J.A. Latham (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation. Bone 35 828-835.
62. S.L. Teitelbaum (2000) Bone resorption by osteoclasts. Science 289 1504-1508.
63. A.S. Truswell (1958) Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg’s disease. J. Bone Joint Surg. Br. 40B 209-218.
64. A.G. Uitterlinden, P.P. Arp, B.W. Paeper, P. Charmley, S. Proll, F. Rivadeneira, Y. Fang, J.B. van Meurs, T.B. Britschgi, J.A. Latham, R.C. Schatzman, H.A. Pols and M.E. Brunkow (2004) Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am. J. Hum. Genet. 75 1032-1045.
65. M.R. Urist (1965) Bone: formation by autoinduction. Science 150 893-899.
66. van Bezooijen, R.L., Heldin, C.-H., ten Dijke, P. (2005). Bone morphogenetic proteins and their receptors. In “Nature Encyclopedia of Life Science.”
67. R.L. van Bezooijen, A.L. Bronckers, F.G. Dikkers, R.A. Gortzak, W. Balemans, S.M. van der Werf, A. Visser, W. Van Hul, H. Hamersma, P. ten Dijke, N.A. Hamdy, S.E. Papapoulos and C.W. Lowik (2007) Sclerostin expression is absent in cementocytes in teeth and in osteocytes in bone biopsies of patients with van Buchem disease. Bone 40 S216.
68. R.L. van Bezooijen, M.C. DeRuiter, N. Vilain, R.M. Monteiro, A. Visser, L. Wee-Pals, C.J. van Munsteren, P.C. Hogendoorn, M. Aguet, C.L. Mummery, S.E. Papapoulos, P. ten Dijke and C.W. Lowik (2007) SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev. Dyn. 236 606-612.
69. R.L. van Bezooijen, B.A. Roelen, A. Visser, L. Wee-Pals, E. de Wilt, M. Karperien, H. Hamersma, S.E. Papapoulos, P. ten Dijke and C.W. Lowik (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199 805-814.
70. R.L. van Bezooijen, J.P. Svensson, D. Eefting, A. Visser, H.G. van der, M. Karperien, P.H. Quax, H. Vrieling, S.E. Papapoulos, P. ten Dijke and C.W. Lowik (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res. 22 19-28.
71. R.L. van Bezooijen, P. ten Dijke, S.E. Papapoulos and C.W. Lowik (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16 319-327.
72. F.S. van Buchem, H.N. Hadders and R. Ubbens (1955) An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol. 44 109-120.
73. L. van Wesenbeeck, E. Cleiren, J. Gram, R.K. Beals, O. Benichou, D. Scopelliti, L. Key, T. Renton, C. Bartels, Y. Gong, M.L. Warman, M.C. De Vernejoul, J. Bollerslev and W. Van Hul (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72 763-771.
74. F.M. Vanhoenacker, W. Balemans, G.J. Tan, F.G. Dikkers, A.M. De Schepper, D.G. Mathysen, A. Bernaerts and W.V. Hul (2003) Van Buchem disease: lifetime evolution of radioclinical features. Skeletal Radiol. 32 708-718.
75. J.E. Wergedal, K. Veskovic, M. Hellan, C. Nyght, W. Balemans, C. Libanati, F.M. Vanhoenacker, J. Tan, D.J. Baylink and W. Van Hul (2003) Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J. Clin. Endocrinol. Metab. 88 5778-5783.
76. D.G. Winkler, M.K. Sutherland, J.C. Geoghegan, C. Yu, T. Hayes, J.E. Skonier, D. Shpektor, M. Jonas, B.R. Kovacevich, K. Staehling-Hampton, M. Appleby, M.E. Brunkow and J.A. Latham (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22 6267-6276.
77. D.G. Winkler, M.S. Sutherland, E. Ojala, E. Turcott, J.C. Geoghegan, D. Shpektor, J.E. Skonier, C. Yu and J.A. Latham (2005) Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J. Biol. Chem. 280 2498-2502.
78. Y. Zhang, Y. Wang, X. Li, J. Zhang, J. Mao, Z. Li, J. Zheng, L. Li, S. Harris and D. Wu (2004) The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol. Cell. Biol. 24 4677-4684.
79. L.B. Zimmerman, J.M. Jesus-Escobar and R.M. Harland (1996) The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86 599-606.